Cancer drugs Flashcards

1
Q

Alkylating agents

A

mechlorethamine (mustargen), Cyclophosphamide (cytoxan), Cisplatin (platinol), Carmustine (BCNU) and Lomustine (CCNU).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alkylating agents characteristics

A

Alkylate the DNA (bind it) and cause miscoding, breakage or crosslinking. Vesicants (caustic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mechlorethamine (mustargen) Characteristics

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mechlorethamine (mustargen) toxicity

A

Hyperuricema which can be treated by alkalizing the urine and trapping it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cyclophosphamide (cytoxan) characteristics

A

Alkylating agent. MOST important cancer drug. Broad spectrum. Needs to be activated by CYP450s so don’t use with an inhibitor. Not vesicant so can be taken orally.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cyclophosphamide (cytoxan) toxicity

A

Hemmorrhagic cystitis (treated with MESNA to bind the by product acrolene and hydration), inappropriate ADH secretion (water toxicity).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cisplatin (platinol) Characteristics

A

Alkylating agent. crosslinks the DNA and makes cells more sensitive to radiation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Testicular cancer DOC

A

Cisplatin (platinol)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cisplatin (platinol) toxicity

A

acoustic nerve damage and anaphylaxis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Carmustine (BCNU), Lomustine (CCNU) characteristics

A

Alkylating agents. Nitrosoureas. Highly lipid soluble. Effective for brain cancer (crosses the BBB) and GI cancers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Carmustine (BCNU), Lomustine (CCNU) toxicity

A

PROFOUND myelosuppression.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Antimetabolites

A

Methotrexate, 6-mercaptopurine (purinethol), 5-flourouracil (5-FU).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Methotrexate MOA

A

antimetabolite. inhibits dihydrofolate reductase to reduce the amount of folic acid and thymidylate to block DNA/RNA/protein synthesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Methotrexate characteristics

A

Give a large dose to “slam” the tumor then rescue the other cells by giving leucovorin which bypasses the blockade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Methotrexate toxicity

A

hepatotoxic (chronic use), pulmonary damage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

6-mercaptopurine (purinethol) MOA

A

antimetabolite. guanine analogue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

6-mercaptopurine (purinethol) characteristics

A

metabolized by xanthine oxidase. If used with allopurinol to reduce hyperuricemia (xanthine oxidase inhibitor) the toxicity will increase. Have to lower the dose if given with allopurinol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

6-mercaptopurine (purinethol) toxicity

A

Jaundice, interacts with allopurinol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

5-fluorouracil (5-FU) MOA

A

Antimetabolite. inhibits thymidylate synthase and blocks DNA synthesis directly. Cell cycle specific to G1 and S phases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

5-fluorouracil (5-FU) characterisitics

A

Leucovorin increases it’s response because FH4 is needed to form thymidylate synthase complex.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

5-fluorouracil (5-FU) uses

A

broad spectrum. solid tumors and BCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Antibiotics used with cancer

A

Doxorubicin (adriamycin), Bleomycin (blenoxane).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Doxorubicin (adriamycin) MOA

A

Antibiotic. Bulky compound that intercalates into DNA and physically blocks replication and repair.

24
Q

Doxorubicin (adriamycin) Characteristics

A

Generates free radicals whose effects are worsened by iron. Can lead to cardiac toxicity. have to decrease the iron by chelating it, don’t take with iron supplements.

25
Q

Doxorubicin (adriamycin) toxicity

A

Cardiac toxicity (iron)

26
Q

DOC for thyroid cancer

A

Doxorubicin (adriamycin)

27
Q

Bleomycin (blenoxane) MOA

A

Antibiotic. Binds directly to DNA. Cell cycle specific to G2 and M phases. Used orally or injected into the bladder.

28
Q

Bleomycin (blenoxane) uses

A

testicular and ovarian cancers

29
Q

Bleomycin (blenoxane) toxicity

A

Pulmonary fibrosis, anaphylactoid symptoms but little bone marrow suppression.

30
Q

Plant alkaloids MOA

A

block mitosis by interacting with microtubules so the cell can’t divide.

31
Q

Plant alkaloids

A

Vincristine, vinblastine, paclitaxel (taxol).

32
Q

Vincristine/vinblastine MOA

A

Bind tubulin and inhibit microtubule formation

33
Q

Plant alkaloids common toxicity

A

Axonal transport also uses microtubules so causes peripheral neuropathy.

34
Q

Vincristine

A

Plant alkaloid. Low myelosuppression but causes peripheral neuropathy. “crisps the neurons”

35
Q

Vinblastine

A

plant alkaloid. More myelosuppression with less peripheral neuropathy. “blasts the bone”

36
Q

Paclitaxel (taxol) MOA

A

Plant alkaloid. Binds the tubulin/microtubulin and inhibits disassembly which arrests mitosis. Very active but very toxic.

37
Q

Paclitaxel (taxol) toxicity

A

peripheral neuropathy, myalgias, arthralgias and hypersensitivity.

38
Q

Tyrosine Kinase Inhibitors

A

Imantinib (gleevac), and Erlotinib (tarceva)

39
Q

Imantinib (gleevac) MOA

A

TKR inhibitor. inhibits the BCR-Abl fusion protein which is a mutation mainly seen in CML and GI stromal tumors.

40
Q

Imantinib (gleevac) toxicity

A

fluid retention and myalgias.

41
Q

Erlotinib (larceva) MOA

A

blocks ATP binding to the HER1/EGFR tyrosine kinase.

42
Q

Erlotinib (larceva) toxicity

A

severe diarrhea

43
Q

Cetuximab (erbitux) MOA

A

Monoclonal antibody that blocks the EGF receptor and cell growth.

44
Q

Cetuximab (erbitux) toxicity

A

diarrhea and anaphylaxis

45
Q

Bevacizumab (avastin) MOA

A

Monoclonal antibody for VEGF which is needed for angiogenesis and is over expressed in tumor cells. Decreases tumor blood supply and slows growth.

46
Q

Bevacizumab (avastin) uses

A

solid tumors and macular degeneration.

47
Q

Dabrafenib/tramentinib uses

A

treats malignant melanoma

48
Q

Dabrafenib/tramentinib MOA

A

inhibit mutant BRAF kinases that lead to unregulated cell proliferation.

49
Q

Dabrafenib/tramentinib toxicity

A

severe skin toxicity

50
Q

Nivolumab/ipilimumab MOA

A

activate cytotoxic T cells (leads to really bad side effects).

51
Q

Nivolumab/ipilimumab uses

A

malignant melanoma

52
Q

Prednisone MOA

A

antiproliferative.

53
Q

Tamoxifen MOA

A

estrogen receptor blocker in breast tissue

54
Q

Tamoxifen toxicity

A

estrogen agonist in the uterus, hot flashes, uterine hyperplasia.

55
Q

Trastuzumab MOA

A

Antibody to HER2 receptor

56
Q

Trastuzumab toxicity

A

cardiac toxicity (don’t use with doxorubicin)

57
Q

Flutamide MOA

A

anti-androgen used with prostate cancer.